Search / Trial NCT06223906

A Registry Study of Biomarkers in Heart Valve Disease

Launched by BEIJING INSTITUTE OF HEART, LUNG AND BLOOD VESSEL DISEASES · Jan 16, 2024

Trial Information

Current as of October 07, 2024

Recruiting

Keywords

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Patients clinically diagnosed with heart valve disease in Beijing Anzhen Hospital
  • Exclusion Criteria:
  • * Age \< 18 years
  • * Failure to obtain medical records and ultrasound data
  • * Refuse follow-up

About Beijing Institute Of Heart, Lung And Blood Vessel Diseases

The Beijing Institute of Heart, Lung and Blood Vessel Diseases is a leading clinical research organization dedicated to advancing the understanding and treatment of cardiovascular, pulmonary, and hematological conditions. Committed to innovative research and high-quality clinical trials, the Institute collaborates with national and international stakeholders to develop and evaluate novel therapeutic interventions. With a multidisciplinary team of experts, the Institute aims to improve patient outcomes through rigorous scientific inquiry and the translation of research findings into clinical practice. Its focus on patient-centered care and commitment to excellence positions it as a pivotal player in the field of cardiovascular and pulmonary health research.

Locations

Beijing, Beijing, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0